Mingjin Li

Associate Director, Biostatistics
BioMarin Pharmaceutical Inc.

Presentation(s):

• OC 21.2 - Hemostatic results for up to 6 years following treatment with valoctocogene roxaparvovec, an AAV5-hFVIII-SQ gene therapy for severe hemophilia A

  Sunday, July 10, 2022
  3:00 PM – 3:15 PM